Mylan has received the green light from the Food and Drug Administration for a generic version of Novartis’ Exelon Patch (rivastigmine transdermal system).
Teva has introduced generic Uceris (budesonide) extended-release tablets, 9 mg, which is indicated for the induction of remission in patients with active, mild-to-moderate ulcerative colitis.
Adamis Pharmaceuticals has entered into an exclusive distribution and commercialization agreement with Swiss drug company Novartis’ Sandoz division to commercialize Adamis’ Symjepi.
Drug firm Zydus Cadila has received the Food and Drug Administration’s nod for generic Adalat CC (nifedipine extended-release tablets), and for generic Questran (cholestyramine for oral suspension).